ddms has been researched along with 11,12-epoxy-5,8,14-eicosatrienoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, MA; Falck, JR; McGiff, JC; Pomposiello, SI | 1 |
| Certíková Chábová, V; Cervenka, L; Falck, JR; Hammock, BD; Imig, JD; Kompanowska-Jezierska, E; Kopkan, L; Kramer, HJ; Kujal, P; Sadowski, J; Vanecková, I; Vanourková, Z; Vernerová, Z; Walkowska, A | 1 |
2 other study(ies) available for ddms and 11,12-epoxy-5,8,14-eicosatrienoic acid
| Article | Year |
|---|---|
Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR.
Topics: 5,8,11,14-Eicosatetraynoic Acid; 8,11,14-Eicosatrienoic Acid; Acetylcholine; Amides; Animals; Arachidonic Acid; Enzyme Inhibitors; Hypertension; Indomethacin; Male; Nitroprusside; Perfusion; Pressure; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Renal Circulation; Sulfones; Tin Compounds; Vasodilation | 2001 |
Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.
Topics: 8,11,14-Eicosatrienoic Acid; Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Drug Evaluation, Preclinical; Hydroxyeicosatetraenoic Acids; Hypertension; Male; Multiple Organ Failure; Norepinephrine; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renal Circulation; Sulfones; Vasoconstrictor Agents | 2010 |